Clay Siegall is one of the most renowned scientists and highly credible personalities in the field of biotechnology and pharmaceutical industry. He is the founder as well as the CEO of one of the fastest growing companies in the biotechnology sector in the United States, named Seattle Genetics. One of the focuses of Seattle Genetics is to make developments in the field of medicine that hasn’t seen much progress in the last few years and help develop effective therapies for cancer therapies and other terminal illnesses. He holds B.S. in Zoology and Ph.D. from the George Washington University.
Under the leadership of Clay Siegall, Seattle Genetics has achieved great heights of success and also managed to get the FDA approval for their proprietary antibody drug conjugate. At present, the antibody conjugate developed by Seattle Genetics is marketed nationally as well as internationally through the approved indications. Clay Siegall understands that to grow and expand in a competitive pharmaceutical industry, Seattle Genetics has to invest heavily into research and development as well as collaborate with other market leaders. It is for this reason; Clay Siegall managed to partner with other major pharmaceutical companies such as Bayer, Genentech, and Pfizer. It helped in the positioning of Seattle Genetics in the pharmaceutical industry and creating a positive image of the enterprise nationally and internationally.
Seattle Genetics has been working tirelessly to get approval for many of its products, and there are many other drugs that are under development at the moment. One of the reasons why Seattle Genetics has achieved success in a short period is because of the emphasis of the company on research and development, which has helped the company to develop some of the most effective drugs on the planet. One of the reasons why Clay Siegall wanted to pursue his career in medical science is because his family member was affected by Cancer, and he saw how chemotherapy was more destructive than cancer. It is for this reason, cancer therapies remain one of the primary focuses of the Seattle Genetics. Thanks to the marketing and business skills of Clay Siegall, he has been able to raise funds of more than a billion dollar for the company till date.